All In Biotech

Drug Trial Radar · NCT05935917

Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults

A Phase 1, Open-label, Single-dose, Randomized, Two-period, Crossover Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Jan 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

44

Actual

Start

May 30, 2023

Primary completion

Aug 14, 2023

Study completion Sep 27, 2023

Sponsor

Lead sponsor
Emergent BioSolutionsIndustry
Sponsor type
Industry
First posted
Jul 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate whether both Form H and Form II, 100mg brincidofovir tablets are bioequivalent, when given under fasting conditions in healthy adults. Participants will be randomized to each receive one tablet of Form H and one tablet of Form II,14 days apart and undergo pharmacokinetic testing pre-dose and post-dose to evaluate safety. This is an open-label, single-dose, randomized, two-period, crossover study.

Conditions

  • Smallpox

Interventions

  • BrincidofovirDrug

    100 mg tablet of Form H and 100 mg tablet of Form II

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK endpoint - Peak Plasma Concentration (Cmax)Time frame: Through 96 hours post-dose
  2. PK endpoint - AUClastTime frame: Through 96 hours post-dose
  3. PK endpoint - AUCinfTime frame: Through 96 hours post-dose
  4. Incidence of treatment adverse events (AEs)Time frame: Through end of study visit (within 14 days after 2nd dose)
  5. Descriptive statistical summary abnormal Heart RateTime frame: Through end of study visit (within 14 days after 2nd dose)
  6. Descriptive statistical summary abnormal Respiratory RateTime frame: Through end of study visit (within 14 days after 2nd dose)
  7. Descriptive statistical summary abnormal Systolic Blood Pressure and Diastolic Blood Pressure (mmHg)Time frame: Through end of study visit (within 14 days after 2nd dose)
  8. Descriptive statistical summary abnormal Body Temperature (Celsius)Time frame: Through end of study visit (within 14 days after 2nd dose)
  9. Chemistry parameters: Total Protein, Albumin, Globulin (g/dL)Time frame: Through end of study visit (within 14 days after 2nd dose)
  10. Chemistry parameter: Albumin/Globulin ratioTime frame: Through end of study visit (within 14 days after 2nd dose)
  11. Chemistry parameters: alkaline phosphatase, ALT, AST, GGT and Creatine phosphokinase (U/L)Time frame: Through end of study visit (within 14 days after 2nd dose)
  12. Chemistry parameters: bilirubin (total and direct), BUN, serum calcium, glucose (random), serum phosphate, serum uric acid and serum magnesium (mg/dL)Time frame: Through end of study visit (within 14 days after 2nd dose)
  13. Chemistry parameters: serum chloride, CO2, serum sodium and serum potassium (mmol/L)Time frame: Through end of study visit (within 14 days after 2nd dose)
  14. Chemistry parameter: Creatinine (g/24h)Time frame: Through end of study visit (within 14 days after 2nd dose)
  15. Chemistry parameter: eGFR (ml/min)Time frame: Through end of study visit (within 14 days after 2nd dose)
  16. Chemistry parameter: LDH (units/L)Time frame: Through end of study visit (within 14 days after 2nd dose)
  17. Hematology parameters: basophils, eosinophils, lymphocytes, monocytes and neutrophils (cells/uL)Time frame: Through end of study visit (within 14 days after 2nd dose)
  18. Hematology parameters: leukocytes and platelets (thousand/uL)Time frame: Through end of study visit (within 14 days after 2nd dose)
  19. Hematology parameters: proportion of basophils, eosinophils, lymphocytes, monocytes and neutrophilsTime frame: Through end of study visit (within 14 days after 2nd dose)
  20. Hematology parameter: erythrocytes (million/uL)Time frame: Through end of study visit (within 14 days after 2nd dose)
  21. Hematology parameter: erythrocytes mean corpuscular volume (MCV) (fL)Time frame: Through end of study visit (within 14 days after 2nd dose)
  22. Hematology parameter: hematocrit (%)Time frame: Through end of study visit (within 14 days after 2nd dose)
  23. Hematology parameter: hemoglobin (g/dL)Time frame: Through end of study visit (within 14 days after 2nd dose)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Altasciences

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.